Exhibit 4.1


 


EXECUTION


 


SECURITIES PURCHASE AGREEMENT


 


This Securities Purchase
Agreement (this “Agreement”) is dated as of May 24, 2012 between Rosetta Genomics Ltd., an Israeli corporation
(the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors
and assigns, a “Purchaser” and collectively the “Purchasers”).


 


 WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined
below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase
from the Company, securities of the Company as more fully described in this Agreement.


 


 NOW, THEREFORE, in consideration
of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the Company and each Purchaser agree as follows:


 


ARTICLE I.



DEFINITIONS


 


1.1.Definitions.  In
addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:


 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.


 


“Board of
Directors” means the board of directors of the Company.


 


“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York or in the State of Israel are authorized or required by law or other
governmental action to close.


 


“Closing”
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.


 


“Closing Date”
means the third Trading Day following the date hereof or such other date as the Placement Agent and the Company may agree in writing,
in either case, on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations
to deliver the Shares, in each case, have been satisfied or waived.


 


“Commission”
means the United States Securities and Exchange Commission.


 


“Company
Counsel” means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, with offices located at One
Financial Center, Boston, MA 02111.


 


“Disclosure
Schedules” means the Disclosure Schedules of the Company, if any, delivered concurrently herewith.


 


“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder.



    	- 1 -



    	 



    
 


“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.


 


“Material
Adverse Effect” means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform
in any material respect on a timely basis its obligations under any Transaction Document. For the purpose of this Agreement, the
terms Material Adverse Effect or material adverse change shall not include any such effects resulting, directly or indirectly,
from the filing of the Prospectus Supplement or the performance of the transactions contemplated by, or pursuant to, the Placement
Agent Agreement or the this Agreement.


 


“Ordinary
Shares” means the ordinary shares of the Company, par value NIS 0.6 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed prior to the Closing.


 


“Per Share
Purchase Price” equals $3.50, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Ordinary Shares that occur after the date of this Agreement and prior to the Closing.


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


“Placement
Agent” means Aegis Capital Corp.


 


“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.


 


“Prospectus”
means the most recent prospectus filed for the Registration Statement (including the documents incorporated by reference therein).


 


“Prospectus
Supplement” means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with
the Commission and delivered by the Company to each Purchaser at or prior to the Closing (including the documents incorporated
by reference therein).


 


“Registration
Statement” means the effective registration statement on Form F-3 with Commission (file no. 333-163063) which registers
the sale of the Shares to the Purchasers (including the documents incorporated by reference therein).


 


“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended or interpreted from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.


 


“Rule 424”
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended or interpreted from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.


 


“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.



    	- 2 -



    	 



    
 


“Shares”
means the Ordinary Shares issued or issuable to each Purchaser pursuant to this Agreement.


 


“Short Sales”
means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to
include the location and/or reservation of borrowable Ordinary Shares). 


 


“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares hereunder as specified below on the signature
page of this Agreement in United States dollars and in immediately available funds.


 


“Subsidiaries”
means the subsidiaries listed in Exhibit 8.1 to the Company’s Annual Report on Form 20-F for the year ended December 31,
2011.


 


“Trading Day”
means a day on which the principal Trading Market is open for trading.


 


“Trading Market”
means the principal trading market in the United States on which the Ordinary Shares are listed or quoted for trading on the date
in question.


 


“Transaction
Documents” means this Agreement and any other documents or agreements executed in connection with the transactions contemplated
hereunder.


 


“Transfer
Agent” means American Stock Transfer & Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 6201 15th Avenue, Brooklyn, NY 11219 and a facsimile number of (718) 921-8334, and any successor transfer agent of the
Company.


 


ARTICLE II.



PURCHASE AND SALE


 


2.1.Closing.  On
the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, an aggregate of 570,755 Shares.  Each Purchaser shall deliver to the
Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser’s Subscription Amount
as set forth on the signature page hereto executed by such Purchaser and the Company shall deliver to each Purchaser its respective
Shares as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth
in Section 2.2 deliverable at the Closing.  Upon satisfaction of the covenants and conditions set forth in Section
2.2 and Section 2.3, the Closing shall occur at the offices of Zysman Aharoni Gayer and Sullivan & Worcester LLP,
counsel for the Placement Agent, located at 1290 Avenue of the Americas, 29th Floor, New York, NY 10104, or such other
location as the parties shall mutually agree.


 


2.2.Deliveries.


 


(a)On or prior
to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:


 


(i) this
Agreement duly executed by the Company;


 


(ii) a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via
The Depository Trust Company Deposit or Withdrawal at Custodian system (“DWAC”) Shares equal to such Purchaser’s
Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser; and



    	- 3 -



    	 



    
 


(iii) the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).


 


(b)On or prior to
the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company such Purchaser’s Subscription Amount
by wire transfer to the account designated in writing by the Company.


 


2.3.Closing
Conditions.


 


(a)The obligations
of the Company hereunder in connection with the Closing with respect to each Purchaser are subject to the following conditions
being met:


 


(i)the accuracy in
all material respects on the Closing Date of the representations and warranties of such Purchaser contained herein (unless as of
a specific date therein in which case they shall be accurate as of such date);


 


(ii)all obligations,
covenants and agreements of such Purchaser required to be performed at or prior to the Closing Date shall have been performed;


 


(iii)the delivery
by such Purchaser of such Purchaser’s Subscription Amount; and


 


(iv)in the event
that, upon the issuance of the Shares to such Purchaser, such Purchaser will hold 5% or more of the Company’s issued share
capital or of the voting rights in the Company, then the delivery by such Purchaser of the Undertaking (as defined in Annex
A attached hereto) towards the OCS (as defined below) substantially in the form attached hereto as Annex A executed
by such Purchaser.


 


(b)The respective
obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:


 


(i)the accuracy in
all material respects when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);


 


(ii)all obligations,
covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;


 


(iii)the delivery
by the Company of the items set forth in Section 2.2(a) of this Agreement; and


 


(iv)there shall have
been no Material Adverse Effect with respect to the Company since the date hereof.


 


ARTICLE III.



REPRESENTATIONS AND WARRANTIES


 


3.1.Representations
and Warranties of the Company. The Company hereby represents and warrants to each Purchaser as follows. The following representations
and warranties also apply to each Subsidiary, whether so expressed or not, unless the context clearly requires otherwise.



    	- 4 -



    	 



    
 


(a)Organization,
Good Standing and Power; Subsidiaries.  The Company has been duly incorporated or organized, is validly existing
as a corporation or other legal entity in good standing (or the foreign equivalent thereof) under the laws of its jurisdiction
of incorporation and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business
as it is now being conducted.  The Company is duly qualified as a foreign corporation to do business and is in good standing
in every jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary
except for any jurisdiction(s) (alone or in the aggregate) in which the failure to be so qualified will not have or reasonably
be expected not to have a Material Adverse Effect. 


 


The Subsidiaries are
all of the direct and indirect subsidiaries of the Company. The Company (i) owns, directly or indirectly, all of the capital stock
or other equity interests of each Subsidiary free and clear of any Liens (as such term is defined below), and (ii) all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities, except in the case of both (i) and (ii), as set forth in that certain
Security Interest Agreement, dated January 26, 2012, or as otherwise described in the Registration Statement and the Prospectus.


 


(b)Authorization;
Enforcement.  The Company has the requisite corporate power and authority to enter into and perform this Agreement
and to issue and sell the Shares in accordance with the terms hereof.  The execution, delivery and performance of this
Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly and validly authorized
by all necessary corporate action, and no further consent or authorization of the Company or its Board of Directors or stockholders
is required in connection therewith.  This Agreement has been duly executed and delivered by the Company.  This
Agreement constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship,
receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by
equitable principles of general application and insofar as indemnification and contribution provisions may be limited by applicable
law.


 


(c)Capitalization.  As
of May 23, 2012 but prior to the issuance of any Shares pursuant to this Agreement, the authorized capital stock of the Company
consists solely of 20,000,000 Ordinary Shares, par value NIS 0.6 per share, of which 1,874,011 Ordinary Shares are issued and outstanding.
No preferred shares are authorized.


 


The charter documents
of the Company currently on file with the Commission (the “Charter Documents”) are true and correct.  All
of the outstanding Ordinary Shares have been duly and validly authorized and are fully paid and non-assessable.  None
of the Ordinary Shares are subject to preemptive rights, except as set forth in that certain Secured Loan Agreement, dated January
26, 2012, or as otherwise described in the Registration Statement and the Prospectus.  No Ordinary Shares are entitled
to registration rights.  The Company is not a party to, and it has no knowledge of, any agreement restricting the voting
of any Ordinary Shares or restricting the transfer of its securities.


 


(d)Issuance
of the Shares.  At Closing, the Shares to be sold to the Purchaser will be duly and validly authorized by all necessary
corporate action and, when paid for in accordance with the terms hereof, will be validly issued and outstanding, fully paid and
non-assessable.


 


(e)No Conflicts.  The
execution, delivery and performance of the Agreement by the Company, and the performance by the Company of its obligations contemplated
herein do not and will not (i) violate any provision of the Charter Documents, (ii) conflict with, or constitute a default under
any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which
the Company is a party, or (iii) create or impose a lien, mortgage, security interest, charge or encumbrance of any nature on any
property of the Company under any agreement or any commitment to which the Company is a party or by which the Company is bound
or by which any of its respective properties or assets are bound, except, with respect to clauses (ii) and (iii) above, to the
extent any such contravention would not result in a Material Adverse Effect.



    	- 5 -



    	 



    
 


(f)Financial
Statements.  The Company’s audited financial statements for the fiscal years ended December 31, 2009, 2010
and 2011 on file with the Commission have been prepared in accordance with accounting principles generally accepted in the United
States (“GAAP”) applied on a consistent basis during the periods involved (except as may be otherwise indicated
in such financial statements or the notes thereto).  Since the date of the latest audited financial statements on file
with the Commission, except as specifically disclosed in a subsequent SEC Report (as defined below) filed prior to the date hereof,
(i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material
Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued
expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected
in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company
has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other
property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock
and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company
stock option plans.


 


(g)Title to
Assets.  The Company has good and marketable title to all of its owned real and personal property whether tangible
or intangible (collectively, the “Assets”), free and clear of any mortgages, pledges, charges, liens, security
interests, claim, community property interest, condition, equitable interest or other encumbrances, license, option, right of first
refusal or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other
attribute of ownership (“Liens”), except as set forth in that certain Security Interest Agreement, dated January
26, 2012, or such as are described in the Registration Statement and the Prospectus.


 


(h)Taxes.  The
Company has accurately prepared and filed all material foreign, federal, state income and all other tax returns, reports and declarations
required by law to be paid or filed by it by any jurisdiction to which the Company is subject.  The Company has no knowledge
of any assessments, adjustments or contingent tax liability (whether federal or state) of any nature whatsoever, whether pending
or threatened against the Company for any period, nor of any basis for any such assessment, adjustment or contingency.  The
Company has complied in all material respects with all applicable legal requirements relating to the payment and withholding of
taxes and, within the time and in the manner prescribed by law, has withheld from wages, fees and other payments, and paid over
to the proper governments or regulatory authorities, all amounts required.


 


(i)Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filings required pursuant to Section 4.1 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement,
(iii) the filings with the NASDAQ Stock Market, Inc., (iv) such filings as are required to be made under applicable state securities
laws, (v) the waiver of preemptive rights pursuant to that certain Secured Loan Agreement, dated January 26, 2012, or (vi) filings
required by the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor (“OCS”) (collectively,
the “Required Approvals”).



    	- 6 -



    	 



    
 


(j)SEC Reports.
The Company has filed with the Commission all reports, schedules, forms, statements and other documents required to be filed by
the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, since January
1, 2010 (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
the Prospectus and the Prospectus Supplement, being collectively referred to herein as the “SEC Reports”) on
a timely basis. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading.


 


(k)Litigation.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company its Subsidiaries, or its properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign, including FINRA) (collectively, an
“Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction
Documents or the Shares or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material
Adverse Effect. None of the Company and its directors and officers, in their capacities as such, is or has been the subject of
any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
or FINRA involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop
order or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or
the Securities Act.


 


(l)Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All disclosures furnished by or on behalf of the Company to the Purchasers
regarding the Company, its business and the transactions contemplated hereby are true and correct and did not and do not contain
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during
the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has
made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth
in Section 3.2 hereof.


 


(m)No Integrated
Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the
Shares to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any
Trading Market on which any of the securities of the Company are listed or designated.



    	- 7 -



    	 



    
 


(n)Patents and
Trademarks. To the knowledge of the Company, the Company owns or has the right to use all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property
rights and similar rights necessary or material for use in connection with its business (collectively, the “Intellectual
Property Rights”). Except as otherwise disclosed in writing to the Placement Agent, (i) the Company has not received
a notice (written or otherwise) that any of the Intellectual Property Rights used by the Company violates or infringes upon the
rights of any Person and (ii) the Company is unaware of any infringements by a third party of any of the Company’s Intellectual
Property Rights. To the knowledge of the Company, all of its Intellectual Property Rights are enforceable. The Company and its
Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
property. Notwithstanding the above, the Company participates in a consortium which is supported by the OCS. The consent of the
OCS will be required for the transfer of know how developed in the framework of the consortium or rights to manufacture based on
and/or incorporating such know how to third parties who are not members of the consortium.


 


(o)Regulation
M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with
the placement of the Shares.


 


3.2.Representations
and Warranties of the Purchasers.  Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants
as of the date hereof and as of the Closing Date to the Company as follows:


 


(a)Organization;
Authority.  Such Purchaser, if an entity, is an entity duly incorporated or formed, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement
and otherwise to carry out its obligations hereunder and thereunder. Such Purchaser is not in Israel or an Israeli citizen, corporation
or resident, or controlled by an Israeli citizen, corporation or resident. The execution and delivery of this Agreement and performance
by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser.  Each Transaction Document
to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms
hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its
terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.


 


(b)Understandings
or Arrangements.  Such Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation
and warranty not limiting such Purchaser’s right to sell the Shares in compliance with applicable federal and state securities
laws).  Such Purchaser is acquiring the Shares hereunder in the ordinary course of its business.


 


(c)Trading Activities.  The
Purchaser’s trading activities with respect to the Shares shall be in compliance with all applicable federal and state securities
laws.  



    	- 8 -



    	 



    
 


(d)Confidentiality.  Other
than to other Persons party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it
in connection with this transaction (including the existence and terms of this transaction).


 


(e)Estimates;
Forward-Looking Statements.  The Purchaser acknowledges that any and all estimates or forward-looking statements
or projections with which it may have been provided (collectively, the “Information”) were prepared by the Company
in good faith, but that the attainment of any such projections, estimates or forward-looking statements cannot be guaranteed, will
not be updated by the Company and should not be relied upon.  The Purchaser further acknowledges that any and all information
regarding the historical performance of the Company is not necessarily indicative of future performance.


 


(f)No Representations.  No
oral or written representations have been made, or oral or written information furnished, to the Purchaser or its advisors, if
any, in connection with the offering of the Shares which are in any way inconsistent with the information contained in the Prospectus.


 


ARTICLE IV.



OTHER AGREEMENTS OF THE PARTIES


 


4.1.Securities
Laws Disclosure; Publicity.  The Company shall (a) by 9:00 a.m. (Eastern time) on the Trading Day immediately following
the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Form
6-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act.
Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser,
except (a) as required by federal securities law in connection with the filing of final Transaction Documents (including signature
pages thereto) with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations.


 


4.2.Indemnification
of Purchasers.   Subject to the provisions of this Section 4.2, the Company will indemnify and hold each
Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls
such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser
Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses,
including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation
that any such Purchaser Party may suffer or incur (but specifically excluding any incidental, indirect,
punitive, special or consequential damages) as a result of or relating to any breach
of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction
Documents.


 


4.3.Equal Treatment
of Purchasers.  No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of any of this Agreement unless the same consideration
is also offered to all of the parties to this Agreement.  For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to
treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Shares or otherwise.



    	- 9 -



    	 



    
 


4.4.Certain
Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company’s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.1.  Each Purchaser, severally and not jointly with the other Purchasers, covenants that until
such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press
release as described in Section 4.1, such Purchaser will maintain the confidentiality of the existence and terms of this
transaction and the information included in the Disclosure Schedules. 


 


4.5.Placement
Agent. In consideration for acting as placement agent in connection with the sale of the Shares hereunder, the Placement Agent
shall receive a commission of seven percent (7%) of the gross proceeds raised in this offering of Shares, plus up to $15,000 reimbursement
for expenses incurred by the Placement Agent, as well as warrants to purchase 14,269 Ordinary Shares exercisable within one year
from Closing at an exercise price of $14.375 per Ordinary Share.


 


4.6.5% Holders.
In the event that, upon the issuance of the Shares to a Purchaser, such Purchaser will hold 5% or more of the Company’s issued
share capital or of the voting rights in the Company, then, upon and as a condition to such issuance, such Purchaser shall deliver
to the Company an executed copy of an Undertaking (as defined in Annex A attached hereto) towards the OCS substantially
in the form attached hereto as Annex A.


 


ARTICLE V.



MISCELLANEOUS


 


5.1.Termination. This
Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not
been consummated on or before June 4, 2012; provided, however, that no such termination will affect the right of
any party to sue for any breach by any other party (or parties).


 


5.2.Fees and
Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement.  The Company shall pay all Transfer
Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the
Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the
delivery of any Shares to the Purchasers.


 


5.3.Entire Agreement. The
Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain
the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.



    	- 10 -



    	 



    
 


5.4.Notices.  Any
and all notices or other communications or deliveries required or permitted to be provided hereunder by the Company to a Purchaser
shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or
communication is delivered via fax at the fax number set forth on the signature pages attached hereto at or prior to 5:30 p.m.
(Eastern time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered
via fax at the fax number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30
p.m. (Eastern time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.  The
address for such notices and communications to the Purchasers shall be as set forth on the signature pages attached hereto.


 


5.5.Amendments;
Waivers.  No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Purchasers holding at least a majority in interest of the Shares based
on the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived
provision is sought.  No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair
the exercise of any such right.


 


5.6.Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.


 


5.7.Successors
and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns.  The Company may not assign this Agreement or any rights or obligations hereunder without the prior
written consent of each Purchaser (other than by merger).  Any Purchaser may assign any or all of its rights under this
Agreement to any Person to whom such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing
to be bound, with respect to the transferred Shares, by the provisions of the Transaction Documents that apply to the “Purchasers.”


 


5.8.No Third-Party
Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.2 and this Section 5.8.


 


5.9.Governing
Law.  All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to
the principles of conflicts of law thereof.  Each party agrees that all legal proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought
against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents)
shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with
respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding.  Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.  If
either party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then the prevailing
party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other
costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.



    	- 11 -



    	 



    
 


5.10.Survival.  The
representations and warranties contained herein shall survive the Closing and the delivery of the Shares.


 


5.11.Execution.  This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood
that the parties need not sign the same counterpart.  In the event that any signature is delivered by fax or by e-mail
delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such fax or “.pdf” signature page
were an original thereof.


 


5.12.Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.


 


5.13.Remedies.  In
addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the
Purchasers and the Company will be entitled to specific performance under the Transaction Documents.  The parties agree
that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in
the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.


 


5.14.Independent
Nature of Purchasers’ Obligations and Rights.  The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under any Transaction Document.  Each Purchaser
has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents.


 


5.15.Saturdays,
Sundays, Holidays, etc.  If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.



    	- 12 -



    	 



    
 


5.16.WAIVER OF
JURY TRIAL.  IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.


 


[Signature pages immediately follow.]



    	- 13 -



    	 



    
 


IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.


 


	
        ROSETTA GENOMICS LTD.

         
	
         

         

	
        By:______________________

             Name: Kenneth
        A. Berlin

             Title: Chief
        Executive Officer
	 
	 	 
	
        Address for notice:

        10 Plaut Street, Science Park

        Rehovot 76706 POB 4059, Israel

        Attention: Oded Biran
	 
	 	 
	With a copy to (which shall not constitute notice):	 
	 	 
	
         

        Brian Keane, Esq.

        Mintz, Levin, Cohn, Ferris, Glovsky and
        Popeo, P.C.

        One Financial Center, Boston, MA 02111

         
	 


 


[Purchaser signature pages immediately
follow.]



    	- 14 -



    	 



    
 


[Purchaser signature pages to Rosetta
Genomics Ltd. Securities Purchase Agreement]


 


IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.


 


Subscription Amount: $ _____________


 


No. of Shares: _____________________


 


Name of Purchaser: ________________________________________________________


 


Signature of Authorized Signatory of Purchaser:
_________________________________


 


Name of Authorized Signatory: _______________________________________________


 


Title of Authorized Signatory: ________________________________________________


 


Email Address of Authorized Signatory:_________________________________________


 


Fax Number of Authorized Signatory: __________________________________________


 


Soc. Sec./Tax ID No.: _______________________________________________________


 


Address for Notice to Purchaser:


 


__________________________


 


__________________________


 


Address for Delivery of Shares to Purchaser
(if not same as address for notice):


 


_________________________



    	- 15 -



    	 



    
 


ANNEX A


 


 


	To:	The Research Committee
	 	The Office of the Chief Scientist
	 	Jerusalem


 


Relating to projects that have been financed
by or are currently being financed by the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (the “OCS”)
_______________ [Please specify project title and OCS’ file number] and to projects of the Company (as this term is defined
below) that may be financed by the OCS in the future (the “Projects”).


 


Undertaking


 


 


We, the undersigned, of _________ [Foreign
investor’s name] a company incorporated, organized and existing under the laws of _______________ and whose registered office
is at _________________ (“______”), having, by an agreement dated __________, committed to invest in __________ Ltd.
(the “Company”), in exchange for [number and type of shares] ________ shares of the Company;


 


Recognizing that the Company’s research
and development Projects are currently, have been or will be financially supported by the Government of the State of Israel, through
the OCS under and subject to the provisions of The Encouragement of Research and Development in Industry Law 5744-1984 (the “R&D
Law”) and the regulations, rules and procedures promulgated there under;


 


Recognizing that the R&D Law places
strict constraints on the transfer of know-how and/or production rights, making all such transfers subject to the absolute discretion
of the OCS’ research committee (the “Research Committee”), acting in accordance with the aims of the R&D
Law and requiring that any such transfer receive the prior written approval of the Research Committee;


 


Hereby declare and undertake:


 


		1.	To observe strictly all the requirements of the R&D Law and the regulations, rules and procedures
promulgated there under, as applied to the Company and as directed by the Research Committee, in particular those requirements
stipulated under Sections 19, 19A and 19B of the R&D Law relating to the prohibitions on the transfer of know-how and/or production
rights.



 


		2.	As a shareholder of the Company, to make all reasonable efforts that the Company shall observe
strictly all the requirements of the R&D Law and the regulations, rules and procedures promulgated there under, as applied
to the Company and as directed by the Research Committee, in particular those requirements stipulated under Sections 19, 19A and
19B of the R&D Law relating to the prohibitions on the transfer of know-how and/or production rights.



 






    	 



    	 



    
 


_______________                               __________________________________


Date  Name
(block letters) and signature of Authorized Company Representative and Company Seal